Dr. Samuel A. Merrill, MD, PhD

Dr. Merrill practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Merrill's NPI, 1144529769, was assigned on March 22, 2011. Dr. Merrill graduated from Washington University School of Medicine in 2011. Dr. Merrill holds West Virginia license 29029.

Dr. Merrill's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Merrill's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Merrill is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Merrill to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merrill practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Merrill's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Merrill's licenses on file in 3 states: West Virginia, Maryland and Vermont.

CMS data shows 211 Medicare services from Dr. Merrill across 5 procedure codes in 2024, all of them office visits, for 132 Medicare patients. Medicare paid $17,952 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 132 Medicare patients who saw Dr. Merrill in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merrill's median patient age at 62, with 57% women.

In 2024, Dr. Merrill wrote 79 Medicare Part D claims for 19 patients. 59% of them were for generic drugs. CMS names the drug for 56 of them, across 3 drugs with 11 or more claims each, at $160,501 in total drug cost. In 2023, CMS named 36 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Merrill for performance year 2024, reported through an alternative payment model (APM). Dr. Merrill accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merrill as offering telehealth.

Dmand AI links 17 papers to Dr. Merrill, published from 2010 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Lymphohistiocytosis, Hemophagocytic, Pyrazoles and Pyrimidines. Dr. Merrill has published most often in Am J Hematol. Dr. Merrill's most frequent co-authors are Robert A. Brodsky, MD, Rakhi Naik, MD and Satish P. Shanbhag, MD, MPH.

CMS Open Payments shows 10 general payments to Dr. Merrill from 6 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 89% of the total. Alexion Pharmaceuticals, Inc. paid the most, $5,910.

Dr. Merrill graduated from Washington University School of Medicine in 2011.